VASOGEN EXPLODIERT !!!!!!!!!!!!!!!!!!!!!!!!!!!!! - 500 Beiträge pro Seite

[SagDieWahrheit]

wird schon zeit

[SagDieWahrheit]

01.02.2006 12:08
Vasogen`s Phase III SIMPADICO Results to be Presented at Late-Breaking Session of the 55th Annual Scientific Session of the American College of Cardiology

TORONTO, Feb. 1 /PRNewswire-FirstCall/ -- Vasogen Inc. (Nachrichten) (NASDAQ:VSGN; TSX:VAS), a leader in the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease, today announced that the pivotal phase III SIMPADICO trial in peripheral arterial disease (PAD) has been accepted for presentation at a Late- Breaking Clinical Trial session of the 55th Annual Scientific Session of the American College of Cardiology (ACC). The ACC meeting, which is being held in Atlanta from March 11 to 14, 2006, attracts approximately 20,000 cardiovascular professionals from the United States, Canada, and the rest of the world.

The initial results of the SIMPADICO trial of the Company`s Celacade(TM) technology in PAD will be presented by Dr. Jeffrey Olin, on Sunday, March 12, at 2:45 p.m. E.T., at the Georgia World Congress Center. The Company will issue a press release providing details on the trial results at the time of Dr. Olin`s presentation. Dr. Olin is Professor of Medicine at the Mount Sinai School of Medicine, Director of Vascular Medicine at The Zena and Michael A. Wiener Cardiovascular Institute in New York, and Principal Investigator and Chairman of the Steering Committee for the SIMPADICO trial.

"The opportunity to present the SIMPADICO trial results at a Late-Breaking Clinical Trial session of the American College of Cardiology recognizes both the quality of this pivotal study and the growing need for new approaches to treat patients with peripheral arterial disease," stated Dr. Jay H. Kleiman, Chief Medical Officer and Head of Cardiovascular Development of Vasogen Inc. "We now look forward to the analysis and interpretation of the SIMPADICO data and to the presentation of the initial findings from this study at the ACC meeting."

The ACC selects presentations for Late-Breaking Clinical Trial sessions based on the potential of the study to affect clinical practice, the impact and novelty of the research, the rigor of the design/methods, the major clinical endpoints, and the quality of the statistical plan.

The SIMPADICO trial was designed to further investigate the use of Vasogen`s Celacade technology to improve intermittent claudication, a debilitating symptom associated with PAD. SIMPADICO is a double-blind, placebo-controlled trial that enrolled 550 patients at 50 sites in the United States and Canada. The primary endpoint of SIMPADICO is the change in maximum walking distance from baseline to 26 weeks assessed on a constant speed treadmill with increasing grade. The study was also designed to investigate the impact of Celacade on additional endpoints, including PAD and cardiovascular-related events, and quality of life.

Peripheral arterial disease is a serious condition due to impaired blood flow to the lower extremities resulting from atherosclerosis. The disease often leads to reduced mobility and a marked impairment in the ability to undertake basic activities of daily independent living. It is estimated that in the United States alone, PAD affects approximately nine million people, with related healthcare costs exceeding $10 billion annually. The condition is associated with a high level of morbidity, and an estimated 30% of patients diagnosed with PAD will die within five years. Patients also have a six-fold increase in risk of death from cardiovascular disease, and often experience the symptom of intermittent claudication (leg pain on walking). Currently, there are limited effective pharmacological therapies available for the treatment of intermittent claudication, and there is a need for a more effective treatment option.

[Stilcom]

Kann mir jemand sagen, was an der Meldung so positiv ist, dass die Aktie so explodiert. Danke

[dr.wssk]

Das würde mich auch interessieren, aber egal, es geht aufwärts.
be.

[loseit]

Antwort auf Beitrag Nr.: 20.042.335 von dr.wssk am 04.02.06 15:14:52

Leider gings auch genauso wieder abwärts, nachdem klar wurde, dass die in SIMBADICO untersuchte Gehfähigkeit nicht signifikant anstieg.

Ist damit das Medikament generell unwirksam, oder gibt es auch andere Ergebnisse?

Ist die Behandlung wirklich neu/revolutionär?

Der Markt und der medizinische Benefit wären ja gigantisch (Stichwort: Schaufensterkrankheit...).

Wer kann Hintergrundwissen beisteuern?

Gruss Loseit

[loseit]

Antwort auf Beitrag Nr.: 21.026.560 von loseit am 31.03.06 13:01:49

Ist hier niemand weiter?

[Neoe]

Loseit:

Natürlich ist hier jemand. Aus gutem Grund würde ich sagen...

[loseit]

Antwort auf Beitrag Nr.: 21.123.488 von Neoe am 07.04.06 17:08:35

An dem zweifle ich langsam nach 35% Verlust.

Das Scheitern der Gehstudie hat ziemlich eingeschlagen -

ich halte nur noch, weil die objektiv gemessenen Werte angestiegen sind.

Wie seht Ihr die weiteren Aussichten ?

Gruss Loseit

[hri]

scheint wohl ne überreaktion zu sein, hab mal nen paar kilo eingesammelt !

[nkelchen]

Antwort auf Beitrag Nr.: 21.157.221 von loseit am 11.04.06 11:50:33

Du hier?!
Hoffentlich warste nicht mehr drin!
Gruss
nk

[loseit]

Antwort auf Beitrag Nr.: 22.287.892 von nkelchen am 26.06.06 22:04:11

Leider war ich drin.

10 Mille versemmelt.

[nkelchen]

Antwort auf Beitrag Nr.: 22.290.476 von loseit am 27.06.06 08:37:14

Scheisse!

Zur Zeit wird aber auch gnadenlos abgestraft.
Orientiere dich am besten an Insiderkäufen -
ist zwar keine Garantie, aber ein recht brauchbarer Indikator.
Mir war der letzte NBIX crash eine Lehre.
Gruss
nk

[nkelchen]

Vasogen Again Battered By Negative Data On Celacade

http://www.bioworld.com/servlet/com.accumedia.web.Dispatcher…

By Aaron Lorenzo



Washington Editor
Poor Celacade data sank shares of Vasogen Inc., though the company s top executive pointed to a bit of silver lining in this story.

On Monday, its stock (NASDAQ:VSGN) plummeted by 74 percent on negative Phase III data in advanced chronic heart failure patients. That clinical setback represents a delay in a regulatory filing for the technology, which is considered a device, so the shares fell $1.37 to 48 cents.

Initial results from ACCLAIM (Advanced Chronic Heart Failure Clinical Assessment of Immune Modulation Therapy), a 2,414-patient registrational trial conducted in seven countries, showed the product did not reach the primary endpoint of significantly reducing the risk of death and cardiovascular hospitalization in the total population. In a conference call, Vasogen President and CEO David Elsley said he was very disappointed with the overall results.

However, he was encouraged with findings in a pre-stratified subgroup. That s because the primary endpoint was met in 692 patients with New York Heart Association (NYHA) Class II chronic heart failure. Among them, there was a 39.1 percent risk reduction (p=0.0003).

We have a very powerful signal, Elsley told BioWorld Today. He and James Young, the chairman of the study s steering committee, said those particular findings demonstrated Celacade s broad anti-inflammatory effects may be more beneficial in less-advanced patients who are at risk for late-stage disease. Young, who chairs the Cleveland Clinic Foundation s division of medicine, called the data exciting and interesting.

We believe that we have a very powerful basis to do a definitive, follow-on study in this patient population, Elsley added, noting that the company would update its development plans in a few weeks as part of its quarterly conference call with the investment community.

Other patients in the study had NYHA Class III and IV chronic heart failure, though Elsley said the trial was expected primarily to have shown an impact in Class II and III. All patients were on standard-of-care medications for heart failure, including diuretics, beta-blockers and ACE-inhibitors, and many had implanted cardiac defibrillators and/or cardiac resynchronization devices.

Chronic heart failure affects an estimated 5 million Americans and 6.5 million Europeans, and Elsley said about 1 million in each territory are considered Class II. That, he said, represents a very sizable market in and of itself. The five-year survival rate for heart failure patients is only 50 percent.

Vasogen, of Mississauga, Ontario, continues to entertain partnership talks for both territories. Celacade already is approved in Europe, though it is not yet marketed there.

The technology is designed to deliver oxidative stress to a sample of the patient s own cells. During a monthly outpatient procedure, a blood sample is collected using a disposable cartridge and then exposed to oxidative stress before being re-administered through an intramuscular injection.

But this letdown is not the first associated with Celacade. Earlier this year, the company reported a Phase III failure in peripheral arterial disease in which the product missed its primary endpoint of improving patients walking distance over placebo. Final results from the trial, called SIMPADICO (Study of Immune Modulation Therapy in Peripheral Arterial Disease and Intermittent Claudication Outcomes), followed an earlier recommendation to halt administrations after an outside monitoring committee found no efficacy signal. Both news events caused Vasogen s stock to plunge, first 44 percent and then another 24 percent. (See BioWorld Today, Aug. 31, 2005, and March 14, 2006.)

The company, which has dropped Celacade s development in peripheral arterial disease, is continuing data analysis on the heart failure data, and complete results are scheduled for release in September at the World Congress of Cardiology in Barcelona, Spain.

The double-blinded study randomized patients evenly to receive either placebo or Celacade. The time to death or first cardiovascular hospitalization (the primary endpoint) was not significantly different between the Celacade and placebo groups in the intention-to-treat population (p=0.24), nor was there any significant difference between treatment groups for either of the components of the primary endpoint.

In addition to the positive findings in the less-ill subgroup, there was a favorable trend in changes in high-sensitivity C-reactive protein in the overall Celacade group, and it was well tolerated. There were no significant differences in serious adverse events between the two groups.

The company had about $53 million in cash reserves at the end of the last quarter.
Published June 27, 2006



Share Related Items
Market Cap: $ 40.71M

Shares Out: 84.47M

macht nach meiner Rechnung ca. 0,62$ je share
nk

[hri]

premarket

1,5k @ 0,50 im bid

300 @ 0,64 im ask

0,75 müßten heute drinn sein !

[nkelchen]

Antwort auf Beitrag Nr.: 22.297.196 von hri am 27.06.06 13:52:18

Tach hri -
ich befürchte hier ist alles möglich, auch nach unten.
nk

[nkelchen]

http://biz.yahoo.com/prnews/060629/to263.html?.v=31

Yahoo! My Yahoo! Mail Make Yahoo! your home page
Sign In
New User?Sign Up
Finance Home - Help



HomeInvestingNews & CommentaryRetirement & PlanningBanking & CreditLoansTaxesSpecial EditionsColumnistsPersonal FinanceInvesting IdeasMarketsCompany FinancesProvidersGet QuotesSymbol LookupFinance Search



Press Release Source: Vasogen Inc.


Vasogen's ACCLAIM Results to be Presented at the Heart Failure Society of America Meeting in September
Thursday June 29, 11:09 am ET


MISSISSAUGA, ON, June 29 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN - News; TSX:VAS - News), a leader in the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease, today announced that results from the Company's ACCLAIM trial of its Celacade(TM) technology (Celacade) in advanced chronic heart failure have been accepted for presentation at a late breaking clinical trial session of the 10th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) being held in Seattle, Washington from September 10 to 13, 2006.
ADVERTISEMENT





"An oral presentation at a HFSA late breaker clinical trial session provides another excellent opportunity to share the ACCLAIM results with the international cardiology community," stated David Elsley, President and CEO of Vasogen. "We are currently completing the analysis of the ACCLAIM data in preparation for releasing full study results at this venue and at the World Congress of Cardiology in Barcelona, Spain, both in September. Based on our ongoing review of the data, we also look forward to providing an update on our plans to advance the commercial development of Celacade during our second quarter conference call in mid-July."

The ACCLAIM trial enrolled 2,414 patients at 176 cardiac centers throughout North America, Europe, and Israel. The study was a double-blind, placebo-controlled trial designed to definitively assess the impact of Vasogen's Celacade(TM) technology on the risk of death and cardiovascular hospitalizations in patients with advanced chronic heart failure. ACCLAIM enrolled patients with New York Heart Association Class II, III, or IV chronic heart failure and a mean left ventricular ejection fraction of less than 30%, indicating patients with advanced disease. Patients who participated in the ACCLAIM trial were taking pharmaceuticals that reflect the current standard-of- care and many had implanted cardiac defibrillators and/or cardiac resynchronization devices as clinically indicated. Study patients received monthly Celacade treatments in an outpatient clinic.

About the Heart Failure Society of America

The Heart Failure Society of America, Inc. represents the first organized effort by heart failure experts from the Americas to provide a forum for all those interested in heart function, heart failure, and congestive heart failure research and patient care. The Annual Scientific Meeting of the Heart Failure Society of America (HFSA) is the largest meeting in North America of scientists and healthcare professionals devoted to heart failure research.

About Heart Failure

Chronic heart failure (HF) is a major public health problem that imposes a significant burden in terms of morbidity, mortality, and the utilization of health care services. It is one of the most commonly diagnosed medical conditions affecting nearly 5 million Americans and 6.5 million Europeans. Each year, in the U.S. alone, 550,000 new cases of HF are diagnosed and nearly 300,000 deaths are associated with this condition. The five-year survival rate for patients with heart failure is only 50%. Approximately 6.5 million hospital days and up to 15 million office visits are for HF care each year in the United States alone. The health care costs associated with HF are staggering, with $29.6 billion in direct and indirect costs in the United States projected for 2006. Almost 72% ($21.3 billion) of this total represents costs associated with hospital and nursing home care, and physician and other health care professionals. More Medicare dollars are spent for the diagnosis and treatment of HF than for any other diagnosis.

About Vasogen

Vasogen is focused on the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease. The impact of the Company's lead product, the Celacade(TM) technology, on reducing mortality and morbidity in advanced heart failure patients was assessed in the recently completed ACCLAIM trial. Vasogen is also developing a new class of drugs for the treatment of neuro- inflammatory and neuro-vascular disorders. VP025, which is entering phase II clinical development, is the lead product candidate from this new class of drugs.

Certain statements contained in this press release constitute "forward- looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements include, without limitation, summary statements relating to results of the ACCLAIM trial in patients with chronic heart failure, statements on our future plans for Celacade and publication of results from the ACCLAIM trial, statements, concerning our partnering activities, strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management. Results disclosed are based on data analyzed to date and may not be confirmed upon full analysis of the detailed results of the ACCLAIM trial and additional information relating to safety and efficacy of Celacade may be discovered upon further analysis of trial data and upon further review and analysis of additional trial data. In some cases, you can identify forward- looking statements by terminology such as "may", "will", "should", "expects", "plans", "anticipates", "believes", "estimated", "predicts", "potential", "continue", "intends", "could", or the negative of such terms or other comparable terminology. You should not place undue reliance on our forward- looking statements which are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the outcome of further analysis of the ACCLAIM trial results, risks associated with the outcome of our research and development programs, the adequacy, timing and results of our clinical trials, the need for additional capital and the effect of capital market conditions and other factors on capital availability, the potential dilutive effects of any financing, including the convertible notes we issued in October 2005, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of our products, the availability of government and insurance reimbursements for our products, the strength of intellectual property, reliance on subcontractors and key personnel, losses due to fluctuations in the U.S.-Canadian exchange rate, and other risks detailed from time to time in our public disclosure documents or other filings with the Canadian and U.S. securities commissions or other securities regulatory bodies. Additional risks and uncertainties relating to our Company and our business can be found in the "Risks Factors" section of our Annual Information Form and Form 40F for the year ended November 30, 2005 as well as in our later public filings. The forward-looking statements are made as of the date hereof, and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Numerical values indicating the statistical significance ("p-values") of results included in this press release are based on analyses that do not account for endpoint multiplicity, and therefore are for information only and are not intended to be used for any future regulatory submissions or in any future product labeling in jurisdictions where such uses are prohibited.




--------------------------------------------------------------------------------
Source: Vasogen Inc.

[nkelchen]

Antwort auf Beitrag Nr.: 22.360.373 von nkelchen am 30.06.06 13:23:48

http://biz.yahoo.com/cc/5/69985.html

Vasogen Earnings Conference Call (Q2 2006)
Scheduled to start Wed, Jul 12, 2006, 4:30 pm Eastern
Check back at the scheduled start time for
the audio link to appear in this spot.
Add This Event To Your Yahoo! Calendar




After the event has finished, the audio will be available
from this page until Fri, Jul 13, 2007

[hri]

Antwort auf Beitrag Nr.: 22.450.447 von nkelchen am 07.07.06 14:11:04

na hoffentlich bringen die was gutes !

[nkelchen]

http://www.tradingmarkets.com/tm.site/news/TOP%20STORY/30389…

Vasogen Q2 Loss Narrows On Lower Expenses - Update

Wednesday, July 12, 2006; Posted: 06:04 PM

Find out where VSGN is going
Use our most popular trading tool to find
out how VSGN will move in the next
5 days.




Stocks rated 9 and 10 have outperformed the average stock by approximately 14 to 1 since 1995 and ideally are the stocks to focus on each day. Stocks rated 1 and 2 on average have lost money and you want to know these stocks in order to avoid them.

Click here for more details






(RTTNews) - Wednesday after the bell, drug developer Vasogen Inc. (VSGN | charts | news | PowerRating) (VAS.TO) announced second quarter financial results, reporting a loss that was narrower than last year on reduced expenses. However, the company's loss was wider than analysts' expectations.

The Toronto-based company reported that its loss for the quarter narrowed down to C$22.4 million or C$0.26 per share from C$25.1 million or C$0.31 per share in the same period last year. However, the company's loss was wider than the C$0.21 per share consensus estimate of Wall Street analysts.

The company attributed the narrower loss to a reduction in the costs associated with its phase III clinical programs, partially offset by expenses associated with the senior convertible notes.

Vasogen's Research and Development expenditures for the quarter declined to C$11.0 million from C$20.7 million in the year-ago period. The year-over year decline in R&D expense was due to significant reduction in the clinical trial activities relating to its phase III programs.

General and administration expenditures for the quarter were C$5.6 million, compared to C$6.0 million in the year-ago period.

For the six-month ended May 31, 2006 the company's loss narrowed down to C$41.8 million or C$0.49 per share from C$45.0 million or C$0.57 per share in the year-ago period.

The company's Research and Development expenditures for six months decreased to C$22.4 million from C$37.5 million in the comparable period last year.

General and administration expenses for six months were C$10.5 million, compared to C$11.4 million in the year-ago period.

In the first quarter, Vasogen's net loss narrowed down to C$19.3 million or C$0.23 per share from C$19.9 million or C$0.27 per share in the year-ago period. Analysts expected the company to report a loss per share of C$0.31 for the quarter.

On June 26, Vasogen revealed the initial results of its phase III ACCLAIM trial of its experimental drug Celacade for advanced chronic heart failure.

Chronic heart failure is a major public health problem affecting nearly 5 million Americans and 6.5 million Europeans. Each year, in the U.S. alone, 550,000 new cases of heart failure are diagnosed and nearly 300,000 deaths occur as a result of heart failure.

According to the results of the trial, though the ACCLAIM study did not reach the primary endpoint of significantly reducing the risk of death and hospital treatment related to chronic heart failure in the total patient population, the endpoint was achieved in a smaller subgroup of nearly 700 patients.

News about the failure of the ACCLAIM trial to meet the primary end point sent the company's stock down $1.35 to $0.50 on the Nasdaq on June 26.

VSGN closed Wednesday's regular trade up 3.96% or $0.02 at $0.42. The stock gained an additional 1 cent and was at $0.43 in the after-hours.

VAS.TO closed the session up C$0.005 at C$0.47 on the Toronto Stock Exchange.

Copyright(c) 2006 RealTimeTraders.com, Inc. All Rights Reserved

[hri]

VSGN -- Vasogen Inc.
Com (No Par)

COMPANY NEWS AND PRESS RELEASES FROM OTHER SOURCES:

www.streetinvesting.com: Progressive Following on Vasogen Inc.

Jul 13, 2006 (M2 PRESSWIRE via COMTEX) -- Streetinvesting.com is the author of this release. This release is a result of our current concentration on Vasogen Inc. (NASDAQ:VSGN)(TSX:VAS) and their latest corporate developments and market performance. Our goal is to help investors seek a diversified portfolio by introducing techniques to help grasp a better understanding and concept of the market and the daily activities that a public company experiences. The first stage of this process is to continually track Vasogen Inc. and use the information that we may find to our advantage. To learn more and become part of the acclaimed online financial newsletter community, visit www.streetinvesting.com for a complimentary subscription.
Vasogen Inc., a company focused on the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease, was up 3.96% Wednesday, with over 2.04 million shares having traded hands come the toll of the day's closing bell.

Investors watched stocks plunge Wednesday as Wall Street continued to see a rough start to the second-quarter earnings season. A broker's downgrade of Dell drove concerns about the impact of a slowing economy on tech companies, whose shares led the broader market lower and took the Nasdaq composite index to its greatest loss in a month and a loss of more than 5% for the year. Rising oil prices and depleting oil inventories also continued to intensify investors concerns over inflation.

The technology-heavy Nasdaq composite index lost 38.62 points, dropping 1.8%, to 2,090.24 Wednesday, while the Dow Jones industrial average tumbled 121.35, or 1.1%, to 11,013.42. TheStandard & Poor's 500 index also declined, dropping 13.92 points, or 1.1%, to 1,258.60.

As we have mentioned in our complimentary weekly market sentiment however, there is an upside to every market. Investors of Vasogen Inc. experienced this first hand Wednesday, as shareholders embraced positive returns upon the day's market close. This gain was a pleasant change of pace for the Company's shareholders who had watched the stock plummet last month and it showed up hand in hand with new news surrounding the Company's operational results for the second quarter of 2006. Although this company's shareholders have seen an overall decline in share price throughout the past 52 weeks, after taking note of Wednesday's market activity and news, our research team will continue to progressively follow Genesis.

In the most recent news to surface surrounding this Company, which we feel may have had an affect on the day's success in the marketplace, as well as an ongoing affect on shareholder outcome, Vasogen Inc. reported Wednesday the results of operations for the second quarter of 2006. Comparative figures relate to the three- and six-month periods ended May 31, 2006, and to the three- and six-month periods ended May 31, 2005. All dollar amounts referenced herein are in Canadian dollars, unless otherwise stated.

The Company...

Please visit www.streetinvesting.com for a complimentary subscription to access this issuance and other related in-depth articles. Please note that membership does not require credit card information nor does it require a commitment to our service.

We have initiated this news release as a tool to keep investors informed about the market. The information contained herein comes from an unbiased perspective and we do not have a vested interest in the companies mentioned in this release. Becoming a member to www.streetinvesting.com will give you access to all the on-going information and investment news that we come across.

Investors wishing to seek a different approach to their investment theories and concepts and to be informed of unique investment opportunities should also visit www.streetinvesting.com for a free membership.

[hri]

war das heut die wende ?

[hri]

ein hammer ist gestern entstanden, der die trendwende einläuten könnte :

[gekivola]

Antwort auf Beitrag Nr.: 23.146.436 von hri am 28.07.06 10:07:08

Hallo hri -
waren ca. 8k 0,32 zu Handelsschluss.
Hoffentlich hält die 0,30.
geki

[hri]

Antwort auf Beitrag Nr.: 23.146.635 von gekivola am 28.07.06 10:18:31

heute 0,35$, somit wird die DMA50 nach oben gebrochen !

hab jetzt 35k stück billig eingesammelt mit schnitt-ek von 30 oiro-cnt

[gekivola]

Antwort auf Beitrag Nr.: 23.152.472 von hri am 28.07.06 16:20:08

gut gemacht -
mein EK liegt bei 0,365
gk

[hri]

Antwort auf Beitrag Nr.: 23.152.686 von gekivola am 28.07.06 16:33:30

mein gefühl sagt mir, das da ein fetter gewinn drinn ist, schlieslich kommt die von 6$ letztes jahr, man braucht noch etwas geduld :

[gekivola]

Antwort auf Beitrag Nr.: 23.152.686 von gekivola am 28.07.06 16:33:30

$

[DeltaComet]

ich glaub da gibts so ein sprichwort das heist

never catch a falling knive

davon haltet ihr wohl nicht gerade viel wie ich sehe.

[hri]

Antwort auf Beitrag Nr.: 23.155.564 von DeltaComet am 28.07.06 19:52:53

doch, sogar sehr aber bei -95% kann man schon mal reingehen, ich bin nun 3 cnt von break even weg, die kommt wieder warts ab !

[DeltaComet]

ich hoffs für dich

[sneake]

tja und nun wurden sie rausgeschmissen von der nasdaq!!


Vasogen Could Be Delisted From Nasdaq
Friday August 11, 4:14 pm ET
Vasogen Receives Nasdaq Notification of Possible Delisting


MISSISSAUGA, Ontario (AP) -- Medical technology company Vasogen Inc. says it has failed to meet Nasdaq listing requirements for its stock and has until early next year to regain compliance or face possible delisting from the U.S. market.

The company, which trades on the Toronto Stock Exchange and Nasdaq stock markets, said Friday that the Nasdaq has advised the company that its share price has closed below $1 US for the last 30 consecutive business days, failing to meet listing requirements.

Vasogen said the Nasdaq has given the company until next Feb. 5 to regain compliance or face possible delisting on the U.S. market. The company said if at any time before Feb. 5, the bid price of its common shares close at $1 or more for 10 straight business days, it will be back in compliance.

The company, which employed 172 people at the end of its 2005 fiscal year, researches and develops technologies targeting chronic inflammation underlying cardiovascular and neurological disease.

Vasogen shares fell 3 cents, or 7.7 percent, to close at 40 cents on the Nasdaq.

[hri]

heute scheint sie endlich auszubrechen !

[hri]

erstaunlich, der wert macht heut 44% und kein mensch hier !

hab im juli ca. 30 kilo zu im schnitt bei 30 cnt eingesammelt weil er vom hoch letztes jahr ca. 95% verloren hatte und im juni 06 so runtergeprügelt wurde wg. dem schlechten testergebnis. mußte nun 6 wochen warten um auf den ausbruch zu warten und die früchte zu ernten, pünktlich zum fast herbst. und ich denke da ist noch etwas in der luft warum die nun so abgeht, schau mer ma.

[hoffentlichplus]

Antwort auf Beitrag Nr.: 23.692.303 von hri am 30.08.06 22:21:09

wegen dir bin ich auf die aktie aufmerksam geworden und 9k zu 0,40
usc gekauft nich viel aber macht auch mist
ps: schreib bitte wenn du die abstossen willst

[hri]

Antwort auf Beitrag Nr.: 23.693.031 von hoffentlichplus am 30.08.06 23:27:33

ich fang heut schon damit an leicht abzubauen, schau mal hier :

http://www.stockconsultant.com/consultnow/basicplus.cgi?ID=s…

der nächste widerstand soll bei 1,75$ liegen !!

obwohl, wenn wir die 50er DMA auf dayline knacken halt ich kurse um 2$ für möglich, immerhin war sie vor 12 monaten bei 6$

[Maroon]

Antwort auf Beitrag Nr.: 23.696.427 von hri am 31.08.06 10:44:10

Gratuliere dir -
ich Idiot hatte zu 0,40 verkauft..
Gruss
Mn

[hri]

Antwort auf Beitrag Nr.: 23.704.774 von Maroon am 31.08.06 18:00:34

ich bin sie heute alle losgeworden zwischen 0,50 und 0,56

zwar 5 teilausführungen aber war nen volltreffer für mich !

[hri]

ich hoffe ihr seid alle raus, premarket :

0,54/0,57 last 0,54

[int00]

Es gibt wieder News !!!

[int00]

BID/ASK
0,54/0,56 €

[loseit]

Antwort auf Beitrag Nr.: 23.755.482 von int00 am 04.09.06 13:11:29

Kannst Du vergessen.
Sind keine echten Angebote, sondern nur Trader-Zahlen.

Sobald Du einen Kaufauftrag reinstellst, verteuert der Makler automatisch nach oben.

[hri]

Antwort auf Beitrag Nr.: 23.755.482 von int00 am 04.09.06 13:11:29

jou, 5k je im b/a da wär ich meine 30k nie losgeworden, die news sind schön und gut aber das 60er chart sagt mir warten für neueinstieg :

[loseit]

Antwort auf Beitrag Nr.: 23.756.306 von hri am 04.09.06 14:18:09

Du solltest vielleicht sehen, dass Du Deine 30 K möglichst bald loswirst:

http://www.aerzteblatt.de/v4/news/news.asp?id=25530

Die medizinische Technik ist wohl eher was für Gutgläubige...

[hri]

Antwort auf Beitrag Nr.: 23.766.252 von loseit am 05.09.06 09:26:27

wer lesen kann ist klar im vorteil, ich schrieb "da wär ich meine 30k nie losgeworden"

was sagt dir das ?

[loseit]

Antwort auf Beitrag Nr.: 23.766.699 von hri am 05.09.06 09:57:10

Glück für Dich, dass Du jemand gefunden hast...

Hatte auch erst Einstieg erwogen, da der Kursabsturz zu verlockend war, aber das kam nicht von umsonst.

[VanDycke]

Newsnewsnewsheute geht die Post ab
New Data from Vasogen's ACCLAIM Trial in Heart Failure Presented at World Congress of Cardiology 2006


MISSISSAUGA, ON, Sept. 5 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS), a leader in the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease, today announced that new data from the 2,400-patient ACCLAIM trial in chronic heart failure showed that in a major combined subgroup of New York Heart Association (NYHA) Class III/IV patients with no prior history of heart attack and all Class II patients, together comprising more than 50% of the study population, Vasogen's Celacade(TM) technology reduced the risk of death and cardiovascular hospitalization by 31% (n=1,305 patients, p=0.0003). Celacade was also shown to be safe and well tolerated. The results were presented today by Guillermo Torre-Amione MD, PhD, at a late breaking clinical trial Hot Line Session of the World Congress of Cardiology 2006 in Barcelona, Spain.

"The ACCLAIM results provide compelling evidence that Celacade significantly reduces the risk of death and cardiovascular hospitalization in an important group of heart failure patients that remain underserved by available therapies," stated Dr. Torre-Amione, Medical Director, Heart Transplant Program, Methodist DeBakey Heart Center at The Methodist Hospital, and Principal Investigator for the U.S. arm of the ACCLAIM trial. "These findings are consistent with the role that chronic inflammation plays in the development and progression of heart failure and are particularly impressive in the large subgroup of NYHA Class III/IV patients who had not experienced a prior heart attack and in all NYHA Class II patients. These results provide a strong basis for targeting Celacade's novel anti-inflammatory mechanism in this large and well-defined patient population."

As previously reported, the difference in time to death or first cardiovascular hospitalization (the primary endpoint) for the intent-to-treat study population was not statistically significant (p=0.22), however, the risk reduction directionally favoured the Celacade group (hazard ratio=0.92).

New findings presented today demonstrated that Celacade significantly reduced the risk of death or first cardiovascular hospitalization by 26% in patients with non-ischemic heart failure, as indicated by no prior history of heart attack at baseline (n=919 patients, 243 events, p=0.02). As previously reported, in patients with NYHA Class II heart failure at baseline, Celacade was also shown to significantly reduce the risk of death or first cardiovascular hospitalization by 39% (n=689 patients, 216 events, p=0.0003). New data also presented today included a combined analysis of NYHA Class III/IV patients with no prior history of heart attack and all NYHA Class II patients, which demonstrated a 31% reduction in the risk of death or first cardiovascular hospitalization in the Celacade group compared to placebo (n=1,305 patients, 391 events, p=0.0003).

In addition, an exploratory analysis based on pre-specified subgroups, which comprised 72% of the patient population and excluded only those patients in NYHA Class III/IV with a prior history of heart attack and an ejection fraction equal to or below the median (EF less than or equal to 23%), showed that Celacade reduced the risk of death or first cardiovascular hospitalization by 21% (n=1,746 patients, 560 events, p=0.005).

"The consistency and strength of the risk reductions seen across a number of large subgroups in ACCLAIM is very compelling, particularly considering that the patients in this trial were receiving the best standard of care of any heart failure trial I have seen published to date," said Dr. James Young, Chairman, The Cleveland Clinic Foundation, Medical Director, Kaufman Center for Heart Failure, and Chairman of the Steering Committee for the ACCLAIM trial. "Of particular interest is the strong finding in the combined subgroup of patients with non-ischemic cardiomyopathy and those with NYHA Class II symptoms regardless of etiology - results that will now drive the commercial development of Celacade. Based on these findings, we now see an opportunity to benefit a large and rapidly growing segment of the heart failure population, where the risk of mortality and morbidity remains unacceptably high."

Consistent with the impact of Celacade on the risk of mortality and morbidity in major subgroups within the ACCLAIM trial was the finding of a significant improvement in quality of life (as measured by the Minnesota Living with Heart Failure Questionnaire) for the intent-to-treat study population (n=2,408 patients, p=0.04). Celacade was also shown to be safe and well tolerated, and there were no significant between-group differences for any serious adverse events.

"The data presented today provide convincing evidence that Celacade offers therapeutic benefit in the treatment of a large and underserved population of chronic heart failure patients," stated David Elsley, President and CEO of Vasogen. "We believe that the significant risk reduction observed in NYHA Class II patients is sufficiently robust to warrant consideration for regulatory approval in the United States and Canada, and we are now making preparations to meet with the FDA and Health Canada to present these data. Furthermore, we believe that the impact of Celacade on patients with non-ischemic heart failure and those in NYHA Class II offers significant commercial potential in Europe under our existing CE Mark - a strategy we are actively discussing with prospective marketing partners. Finally, based on the ACCLAIM results and recommendations from the Steering Committee, we have commenced planning a follow-on study to support wider adoption in the heart failure population."

Conference Call

As previously announced, a conference call and a web cast with a slide presentation will be conducted on Tuesday, September 5, 2006, at 8:30 a.m. Eastern Time. The slide presentation may be viewed at www.vasogen.com, and the conference call may be accessed by calling 416-695-6130 or 1-800-766-6630, ten minutes prior to the call. An audio web cast of the event will also be available at www.vasogen.com. A re-broadcast of the conference call may be accessed by calling 1-800-293-3630, pin code 9899, and will also be available at www.vasogen.com.

About the ACCLAIM Trial

The double blind, placebo-controlled ACCLAIM trial studied 2,408 subjects with chronic heart failure at 175 clinical centers in seven countries. ACCLAIM was designed to assess the ability of Celacade to reduce the risk of death or first cardiovascular hospitalization. Patients included in the study had New York Heart Association (NYHA) Class II, III, or IV heart failure with a left-ventricular ejection fraction (LVEF) of 30% or less and had been hospitalized or received intravenous drug therapy for heart failure within the previous 12 months, or had NYHA Class III/IV heart failure with a LVEF of less than 25%.

Patients in the ACCLAIM trial were receiving optimal standard-of-care therapy for heart failure, which at baseline included diuretics (94%), ACE-inhibitors (94%), beta blockers (87%), automatic implantable cardioverter defibrillators (26%), and use of cardiac resynchronization therapy (10.5%). The placebo (n=1,204 patients) and Celacade (n=1,204 patients) groups were well balanced for all important baseline characteristics, including demographics, left-ventricular ejection fraction (LVEF), NYHA classification, concomitant medical conditions, medications, and device therapies.

About Chronic Heart Failure

Chronic inflammation is now well recognized as an underlying mechanism contributing to the development and progression of heart failure. Chronic heart failure is a debilitating condition in which the heart's ability to pump blood throughout the body is impaired. Patients with heart failure experience a continuing decline in their health, resulting in an increased frequency of hospitalization and in premature death.

About the Chronic Heart Failure Market

In North America and Europe, chronic heart failure affects approximately twelve million people, thirty three percent of whom have non-ischemic etiology. At any one time, approximately 4.4 million of these patients are in the NYHA Class II stage of disease and 2.4 million patients are NYHA Class III.

In the U.S. alone, the cost of medical care, primarily resulting from hospitalization, is estimated to exceed $25 billion annually and the condition is associated with more than 600,000 deaths each year. Currently, there are no approved therapies that target the chronic inflammation underlying chronic heart failure.

About the European Society of Cardiology and The World Heart Federation

The World Congress of Cardiology 2006 brings together, in a joint meeting, the XVth World Congress of Cardiology of the World Heart Federation and the 2006 Congress of the European Society of Cardiology and is the largest medical meeting in Europe, with more than 25,000 attendees expected.

About Vasogen:

Vasogen is focused on the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease. The recently completed international 2,400-patient ACCLAIM trial assessed the impact of the Celacade technology on reducing the risk of mortality and morbidity in patients with advanced heart failure. Full results for the ACCLAIM study were presented at the World Congress of Cardiology 2006, in Barcelona, Spain, and will be presented at the 10th Annual Scientific Meeting of the Heart Failure Society of America being held in Seattle, Washington on September 13, 2006. Vasogen is also developing a new class of drugs for the treatment of neuro-inflammatory and neuro-vascular disorders. VP025, which is entering phase II clinical development, is the lead product candidate from this new class of drugs.

Certain statements contained in this press release and the upcoming conference call and web cast constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements may include, without limitation, summary statements relating to results of the ACCLAIM trial in patients with chronic heart failure, plans to advance the development of Celacade, statements concerning our partnering activities and health regulatory discussions, strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expects", "plans", "anticipates", "believes", "estimated", "predicts", "potential", "continue", "intends", "could", or the negative of such terms or other comparable terminology. A number of assumptions were made by us in the preparation of these forward-looking statements, including assumptions about the nature of the market for Celacade in the treatment of chronic heart failure, particularly in Europe, the regulatory approval process leading to commercialization and the availability of capital on acceptable terms to pursue the development of Celacade. You should not place undue reliance on our forward-looking statements which are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the outcome of further analysis of the ACCLAIM trial results, the requirement or election to conduct additional clinical trials, the regulatory approval process, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other factors on capital availability, the potential dilutive effects of any financing, including the convertible notes we issued in October 2005, risks associated with the outcome of our research and development programs, the adequacy, timing and results of our clinical trials , competition, , market acceptance of our products, the availability of government and insurance reimbursements for our products, the strength of intellectual property, reliance on subcontractors and key personnel, losses due to fluctuations in the U.S.-Canadian exchange rate, and other risks detailed from time to time in our public disclosure documents or other filings with the Canadian and U.S. securities commissions or other securities regulatory bodies. Additional risks and uncertainties relating to our Company and our business can be found in the "Risk Factors" section of our Annual Information Form and Form 40F for the year ended November 30, 2005, as well as in our later public filings. The forward-looking statements are made as of the date hereof, and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Unless otherwise indicated, numerical values indicating the statistical significance ("p-values") of results included in this document are based on analyses that do not account for endpoint multiplicity.

SOURCE Vasogen Inc.

[VanDycke]

Vorbörslich usa 0,68 370000Stück gehandelt

[VanDycke]

0.5701 VSGN - VASOGEN INC
Change:

% Change:

% High:

0 Low:

0 Volume:

375,956

Price Data Table
Open 0
Previous Close 0.5701
Exchange of Last Sale Pacific
Time of Last Sale 23:59:30
Tick Down
Bid 0.69
Ask
Size Bid/Ask 19x1
Symbol Type Equity

Fundamental Data Table
52 Week High 5.23
52 Week Low 0.27
EPS -0.99
P/E Ratio 0.00
Shares Outstanding 68,000,000
Market Cap 38,968,000
Beta 1.980
Dividend Frequency

[VanDycke]

ist keiner hier oder es interesiert keinen

[cyba]

*meld*

[cyba]

bin mal rein mit einer kleinen position zu 0.69...
schaun mer ma

[hoffentlichplus]

Antwort auf Beitrag Nr.: 23.766.838 von loseit am 05.09.06 10:06:14

bei 15 mio im amiland kriegst du locker 30 k weg

[VanDycke]

news aus can

FP/wire say Spanish trip injects life into Vasogen


2006-09-06 07:38 ET - In the News

[int00]

wenig Volumen aber stabil.
Hier geht noch was

[int00]

Keiner mehr da ?

[int00]

Die Aktie bricht langsam aus, und hier ist nichts los.
Na ja mehr für mich

[dr.wssk]

Solange keine Medikamentenzulassung durch ist, hängt alles am seidenen Faden.
be.

[int00]

Es gibt wieder News.

[dr.wssk]

Antwort auf Beitrag Nr.: 24.861.907 von int00 am 26.10.06 11:12:46

Verrate sie bitte, ich habe nichts gefunden. Danke!
be.

[int00]

Hier der Link.
http://biz.yahoo.com/prnews/061023/to421.html?.v=6

[int00]

Entschuldige falscher Link, hier der Richtige
http://biz.yahoo.com/prnews/061025/to219.html?.v=36

[dr.wssk]

Danke, Vasogen ist eine Spekulation auf Alles oder Nichts. Viele solcher Werte möchte man aber nicht im Depot haben.
be.

[pflicht]

Antwort auf Beitrag Nr.: 24.890.292 von dr.wssk am 27.10.06 15:30:47

Seit einigen Tagen beobachte ich den Kurs von Vasogen.
Irgendein Investmenthaus hat diese Aktie zum Kauf empfohlen.
Auch hier in Deutschland findet ab und zu ein Handel statt.

Auf diesem Board läßt sich keiner mehr sehen.
Kann hier noch ein Gedankenaustausch stattfinden?

Pflicht

[Buddah]

Antwort auf Beitrag Nr.: 28.156.843 von pflicht am 06.03.07 22:56:51

Versiebeneinhalbfacher
Gibt es für "Celacade", einem Mittel gegen Herzerkrankungen, ein Happy Ende, dürften auch die Aktionäre sehr glücklich sein, wenn sie auf den Aktienkurs sehen.
Die Experten des Hot Stocks Investor zitieren die Analysten von Rodman & Renshaw, die für die Aktie von Vasogen (WKN 872281) ein Kursziel von drei US-Dollar beziehungsweise 2,30 Euro ausgeben. Zwar habe das Hauptprodukt, „Celacade“, in Phase-III-Studien zur Behandlung chronisch Herzkranker die klinischen Endziele nicht erreicht, worauf der Aktienkurs seit Sommer 2006 eingebrochen ist, doch habe sich das Präparat in verschiedenen Untergruppen der Versuchspersonen als sicher und effizient erwiesen. Bei einer speziellen Patientengruppe etwa, die zuvor noch keine Herzattacke erlitten hatte, wurde das Risiko eines plötzlichen Herztodes um statistisch signifikante 26 Prozent verringert. In Europa ist der Wirkstoff mit CE-Kennzeichnung zugelassen und dürfte in den kommenden Jahren Marktanteile hinzugewinnen. Die Analysten schätzen, dass Vasogen schon in der ersten Jahreshälfte einen Vertriebspartner für „Celacade“ präsentieren kann und das Mittel auf den europäischen Markt bringt. Alleine in Europa beträgt das Marktpotenzial 182 Millionen Kanadische Dollar pro Jahr, während der Börsenwert von Vasogen bei rund 56 Millionen Kanadischen Dollar liegt.
http://www.deraktionaer.de/xist4c/web/Versiebeneinhalbfacher…

[dr.wssk]

Antwort auf Beitrag Nr.: 28.180.516 von Buddah am 08.03.07 11:42:33

#63: Ich schrieb schon, es ist ein Alles oder Nichts-Wert. Wäre man Arzt, dann könnte man ggf. den medizinischen Hintergrund verstehen. Ansonsten das typische Bild einer Biotech-Firma. Irgendwo habe ich mal gelesen, dass es von 100 Firmen eine schafft. Ob das Vasogen sein wird, weiß nicht, mir ist es eine kleine Spekulation wert.
be.

[blepat]

Vasogen!
Also Leute zum einen mal die Tatsache dass bei Vasogen kürzlich zu einem festen Kurspreis von 47 cts.

Wer das Trading beobachtet weiss dass beim letzten run-up bis auf 48cts die MM short verkauft haben. Danach der unausweichliche Rückfall und jetzt werden die short Positionen gecovert, respektiv akkumuliert.

Dann: Der neue CEO Mr. Terry Gregg hat eine bemerkenswerte Karriere in ähnlichen, sich im Aufbau befindlichen Firmen im Gepäck.

Dies lässt darauf schliessen, dass Vasogen sehr wohl bald einen Vertriebspartner für den Marketing hier in Europa bekanntgeben wird.

KR (Kings Road) wird anfang April die letzte Rückzahlung in Form von Aktien erhalten von dem Revolving Credit von 2005. Dies war eine beständige Belastung für den Kurs.

Dann: Für den 5.April wurde die Jahresversammlung angesetzt. Vielleicht die erhoffte News zu diesem Zeitpunkt?
Und: Es ist geplant (Proxi-voting) im employee stock options plan, Kaufoptionen ans Management zu verteilen. (bis 10mio Optionen?)
Dies deutet darauf hin dass die feste Überzeugung vorliegen dass nach diesem Datum eine funtamental Trendwende anbrechen wird.

3$ Kursziel wie schon hier zu lesen durch R & R.

Zudem ist seit einigen Tagen ein potentieller Käufer am Markt.
Zeitweise flasht auf der bid-Seite eine Nachfrage von 2Mio Aktien zu verzeichnen.

Schaut euch mal die Grafik von ACOR (Nasdaq) an. Diese Aktie stand bei 2.2$ dann kam die Nachricht dass Tests eines Medikamentes gut gelaufen sind. Diese Nachricht hat die Aktie bis auf 25$ katapultiert.

Mit einer Market Cap von nicht mal 60 Mio und mit rund 30mio$ cash ist die Aktie von einem spekulativen Standpunkt aus gesehen sehr billig. Es könnten auch demnächst mal 400 mio werden, dann wären wir beim Kurziel von RR angelangt.

Mein Rating : Wer Vasogen verpasst ist selbst schuld.
(meine Meinung)

[dr.wssk]

#66:
Danke für Deine schöne Zusammenfassung. Insbesondere die englischen Mitteilungen im Web konnte ich nicht alle exakt übersetzen. Auf alle Fälle bleibt es sehr spannend, und ich bleibe dabei.
Gruß,
Bernd

[dr.wssk]

Reverse Splitt am 17.04.07 1:10. Ich sehe das nicht als negativ an.
be.

[dr.wssk]

Es geht los, die EU-Vermarktung ist angekündigt.
be.

[dr.wssk]

Antwort auf Beitrag Nr.: 28.879.736 von dr.wssk am 18.04.07 15:20:47

Und der Kurs kennt zur Zeit nur eine Richtung!!!